2026-06-14T03:40:30Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/90712024-09-27T22:35:09Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Sguassero, Yanina author Roberts, Karen N author Harvey, Guillermina B author Comandé, Daniel author Ciapponi, Agustín author Cuesta, Cristina B author Aguiar, Camila author Castro, Ana M de author Danesi, Emmaría author de Andrade, Ana L author de Lana, Marta author Escribà, Josep M author Fabbro, Diana L author Fernandes, Cloé D author Flores-Chavez, Maria author Hasslocher-Moreno, Alejandro M author Jackson, Yves author Lacunza, Carlos D author Machado-de-Assis, Girley F author Maldonado, Marisel author Meira, Wendell S F author Molina, Israel author Monje-Rumi, María M author Muñoz-San Martín, Catalina author Murcia, Laura author Nery de Castro, Cleudson author Sánchez Negrette, Olga author Segovia, Manuel author Silveira, Celeste A N author Solari, Aldo author Steindel, Mário author Streiger, Mirtha L author Vera de Bilbao, Ninfa author Zulantay, Inés author Sosa-Estani, Sergio author 2018-08 OBJECTIVE: To determine the course of serological tests in subjects with chronic Trypanosoma cruzi infection treated with anti-trypanosomal drugs. METHODS: A systematic review and meta-analysis was conducted using individual participant data. Survival analysis and the Cox proportional hazards regression model with random effects to adjust for covariates were applied. The protocol was registered in the PROSPERO database (http://www.crd.york.ac.uk/PROSPERO; CRD42012002162). RESULTS: A total of 27 studies (1296 subjects) conducted in eight countries were included. The risk of bias was low for all domains in 17 studies (63.0%). Nine hundred and thirteen subjects were assessed (149 seroreversion events, 83.7% censored data) for enzyme-linked immunosorbent assay (ELISA), 670 subjects (134 events, 80.0% censored) for indirect immunofluorescence assay (IIF), and 548 subjects (99 events, 82.0% censored) for indirect hemagglutination assay (IHA). A higher probability of seroreversion was observed within a shorter time span in subjects aged 1-19 years compared to adults. The chance of seroreversion also varied according to the country where the infection might have been acquired. For instance, the pooled adjusted hazard ratio between children/adolescents and adults for the IIF test was 1.54 (95% confidence interval 0.64-3.71) for certain countries of South America (Argentina, Bolivia, Chile, and Paraguay) and 9.37 (95% confidence interval 3.44-25.50) for Brazil. CONCLUSIONS: The disappearance of anti-T. cruzi antibodies was demonstrated along the course of follow-up. An interaction between age at treatment and country setting was found. Int J Infect Dis. 2018 Aug;73:93-101. 10.1016/j.ijid.2018.05.019 1878-3511 1201-9712 International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 29879524 http://hdl.handle.net/20.500.12105/9071 Chronic disease Follow-up studies Individual participant data Meta-analysis Serologic tests Trypanosoma cruzi Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: A systematic review and meta-analysis of individual participant data